Immune cell therapeutics - The Third Affiliated Hospital of Guangzhou Medical University

Drug Profile

Immune cell therapeutics - The Third Affiliated Hospital of Guangzhou Medical University

Alternative Names: CAR-NK; NRC-NK

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator The Third Affiliated Hospital of Guangzhou Medical University
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; NK cell lectin-like receptor subfamily K modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer

Most Recent Events

  • 09 Jun 2017 Preclinical trials in Colorectal cancer in China (Intraperitoneal) (ChiCTR-IID-17011603)
  • 09 Jun 2017 The Third Affiliated Hospital of Guangzhou Medical University plans a phase I trial for Colorectal cancer (Late-stage disease, Metastatic disease) in China (ChiCTR-IID-17011603)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top